Yoshiko Tomita

Yoshiko Tomita

Auto-generated profile, based on publicly available information

Yoshiko Tomita

Clinical Research, Drug Development Division Sumitomo Pharma Co., Ltd. Osaka Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
SASatoshi Asano
Satoshi Asano
AGAleksandra Galetin
Aleksandra Galetin
YTYoshiko Tomita
Yoshiko Tomita
KGKathleen M. Giacomini
Kathleen M. Giacomini
XCXiaoyan Chu
Xiaoyan Chu
YSYuichi Sugiyama
Yuichi Sugiyama
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the K i values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation. However, consensus is lacking on whether these factors should be considered in predicting in vivo inhibition. Physiologically based pharmacokinetic models, combined with the extended clearance concept, have been used and are discussed here for OCT2/MATEs probes. In addition to modeling, early clinical studies use endogenous biomarkers to evaluate transporter‐mediated DDI risk, with the aim of avoiding unnecessary clinical DDI studies. Identified biomarkers for OCT2/MATEs, such as creatinine, N 1 ‐methylnicotinamide, and N 1 ‐methyladenosine, have proven useful in confirming clinically relevant OCT2/MATEs‐mediated DDIs when renal clearance (CLr) is used as an endpoint; their application is discussed further. From a clinical perspective, the intact nephron hypothesis (INH), which postulates that the decrease in CLr in chronic kidney disease (CKD) is proportional to that in nephron numbers, has been proposed. However, reports suggest that the secretion clearance of creatinine and substrates of organic anion transporters (OATs) does not follow this proportionality in patients with CKD. This state‐of‐the‐art review highlights key developments in predicting OCT2/MATEs‐mediated DDIs in healthy volunteers and explores the prediction of clinical OCT2/MATEs DDI risk in patients with CKD by comparing substrate‐dependent changes in secretion clearance for substrates of OCT2/MATEs and OATs. Recommendations for the prediction of OCT2/MATEs‐mediated DDI risk, together with the current knowledge gaps and future directions, are discussed.

27 December 2021 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
YTYoshiko Tomita
Yoshiko Tomita
EHEmma Hansson
Emma Hansson
FMFlorent Mazuir
Florent Mazuir
GWGustaf J Wellhagen
Gustaf J Wellhagen
QOQing Xi Ooi
Qing Xi Ooi
SBSébastien Bolze
Sébastien Bolze
Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal dosing regimen for Japanese patients with T2DM and chronic kidney disease (CKD). Imeglimin plasma concentrations in Japanese and Western healthy volunteers, and patients with T2DM, including patients with mild to severe CKD with an estimated glomerular filtration rate (eGFR) greater than 14 ml/min/1.73 m2were included in a population PK analysis. PK simulations were conducted using a population PK model, and the area under concentration‐time curve (AUC) was extrapolated with power regression analysis to lower eGFR. The influence of eGFR, weight, and age on apparent clearance and of dose on relative bioavailability were quantified by population PK analysis. Simulations and extrapolation revealed that the recommended dosing regimen based on the AUC was 500 mg twice daily (b.i.d.) for patients with eGFR 15–45 ml/min/1.73 m2, and 500 mg with a longer dosing interval was suggested for those with eGFR less than 15. Simulations revealed that differences in plasma AUCs between Japanese and Western patients at the same dose were mainly driven by a difference in the eGFR and that the plasma AUC after 1000 and 1500 mg b.i.d. in Japanese and Western patients, respectively, was comparable in the phase IIb studies. These results indicate suitable dosages of imeglimin in the clinical setting of T2DM with renal impairment.

1 March 1993 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
TKToshiya Katsura
Toshiya Katsura
MTMikihisa Takano
Mikihisa Takano
YTYoshiko Tomita
Yoshiko Tomita
MYMasato Yasuhara
Masato Yasuhara
KIKen-Ichi Inui
Ken-Ichi Inui
RHRyohei Hori
Ryohei Hori

4 April 2022 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Open access
YTYoshiko Tomita
Yoshiko Tomita
TTTakeshi Takagaki
Takeshi Takagaki
AKAtsushi Kitamura
Atsushi Kitamura
EWErika Wada
Erika Wada
HNHironori Nishibe
Hironori Nishibe
YOYoshiro Okubo
Yoshiro Okubo
Background/Purpose: Blonanserin is an atypical antipsychotic, a potent selective antagonist of dopamine D2 receptor (D2), prescribed as oral formulations in patients with schizophrenia. Blonanserin transdermal patch was developed to provide a new treatment option, but the corresponding dose to oral blonanserin was not clear. The aims of this study were to clarify the pharmacokinetic (PK)-pharmacodynamic characteristics of blonanserin after transdermal patch application and to evaluate the corresponding dose to oral formulation based on striatal D2 occupancy. Methods: The relationship between D2 occupancy and plasma blonanserin concentration was analyzed using an E max model based on data from positron emission tomography study with oral and transdermal blonanserin. D2 occupancy was simulated using E max models based on the observed plasma concentrations and the simulated plasma concentrations obtained from population PK model. Results: Plasma blonanserin concentration levels after repeated patch applications were nearly stable throughout the day and no effect of sex, advanced age, or application site was detected. The concentration at half maximal D2 occupancy during transdermal patch applications, 0.857 ng/mL, was higher than that after oral doses, 0.112 ng/mL, suggesting metabolite contribution after oral doses. The median predicted D2 occupancy during blonanserin patch applications at doses of 40 and 80 mg/d was 48.7% and 62.5%, respectively, and the distribution of D2 occupancy at these doses could cover most of that at oral doses of 8 to 24 mg/d. Conclusions: Predicted D2 occupancy suggested that a 40- to 80-mg/d blonanserin transdermal patch dose corresponds to an 8- to 24-mg/d oral dose for the treatment of schizophrenia.

1 December 2015 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
YOYuka Ohata
Yuka Ohata
YTYoshiko Tomita
Yoshiko Tomita
KSKota Suzuki
Kota Suzuki
TMTakashi Maniwa
Takashi Maniwa
YYYoshitaka Yano
Yoshitaka Yano
KSKeisuke Sunakawa
Keisuke Sunakawa

1 August 2020 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
YTYoshiko Tomita
Yoshiko Tomita
MYMasahiro Yahata
Masahiro Yahata
MHMasayo Hashimoto
Masayo Hashimoto
HNHaruka Nishimuta
Haruka Nishimuta
HKHiroko Kawaguchi
Hiroko Kawaguchi
TWTakao Watanabe
Takao Watanabe